Defense Verdict Returned In Testosterone Replacement Therapy Heart Attack Trial
CHICAGO — An Illinois federal jury on Aug. 17 returned a defense verdict for Actavis Inc. in a testosterone replacement therapy (TRT) heart attack case in which the plaintiff opted out...To view the full article, register now.
Already a subscriber? Click here to view full article